ClinicalTrials.Veeva

Menu

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Lilly logo

Lilly

Status and phase

Completed
Phase 2

Conditions

Carcinoma, Non-Small-Cell Lung

Treatments

Drug: cisplatin
Drug: Gemcitabine
Drug: LY293111

Study type

Interventional

Funder types

Industry

Identifiers

NCT00069875
4842
H6H-MC-JEAM

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Non-Small Cell Lung Cancer, Stage IIIB or IV that is not amenable to either surgery of curative intent or radiation therapy
  • Tumor that can be measured by x-ray or scan
  • Adequate organ function

Exclusion criteria

  • Inability to swallow capsules
  • Documented brain metastases
  • Prior chemotherapy or biological therapy for this disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

19

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems